NasdaqGS:GILDBiotechs
Gilead’s Tubulis Deal And New Approvals Reshape Growth And Valuation Story
Gilead Sciences (NasdaqGS:GILD) completed its acquisition of Tubulis, adding next generation antibody drug conjugate technologies to its oncology portfolio.
The company received first in class FDA approval for Hepcludex to treat chronic hepatitis delta virus infection.
Trodelvy received a positive European regulatory recommendation in advanced breast cancer.
Gilead renewed its multi year collaboration with the World Health Organization to combat visceral leishmaniasis.
For investors...